Briakinumab, chemically identified as 339308-60-0, represents a distinct biologic therapy exhibiting significant application in the management of moderate to severe plaque condition and symptomatic alopecia areata . This protein selectively blocks the IL-12 and interleukin pathways, crucial eleme

Rilotumumab, formerly designated AMG 102, is a protein mainly utilized as a useful research instrument to investigate the pathways underlying neoplastic proliferation. This experimental uniquely targets the IGFR, a critical factor in various malignant types . Investigators leverage rilotumumab to

Recombinant murine granulocyte colony-stimulating factor, often abbreviated as G-CSF, represents a valuable therapeutic molecule in modern medicine. Produced via modern biotechnological techniques, this protein is essentially a refined version of a naturally occurring hormone that encourages the